RxDoctor Payments Data

Scott Sanders, MD

Neurology · Lafayette, INNPI 1902800576

Payments from drug & device makers

$5,224in general payments, 2019–2025

Across 323 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$823
  • Lilly USA, LLC$435
  • Biogen$278
  • Novartis$270
  • Biohaven Pharmaceutical Holding Company Ltd.$267
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$1503%
  • Food & beverage$5,07497%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,224 in reported general payments places this provider in the 60th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$307,153
Medicare patients
853
Services billed
5,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant77$95,364
Aimovig AutoinjectorErenumab-Aooe27$20,689
Verapamil Er PmVerapamil Hcl27$10,192
Divalproex Sodium ErDivalproex Sodium316$9,450
Nortriptyline Hcl712$8,488
Amitriptyline Hcl595$6,486
Venlafaxine Hcl ErVenlafaxine Hcl259$3,312
RizatriptanRizatriptan Benzoate33$2,385
Propranolol Hcl ErPropranolol Hcl60$1,950
Verapamil SrVerapamil Hcl25$1,860
Verapamil ErVerapamil Hcl55$1,731
Naratriptan Hcl18$1,101
Gabapentin64$1,065
Topiramate73$800
Ondansetron OdtOndansetron37$714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$1,915$95,36477 claims
Upsher-smith Laboratories LLCTopiramate$133$80073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 308 neurology providers in Indiana.

Other neurology in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →